1 Low muscle strength is associated with cardiovascular autonomic neuropathy in patients with type 2 diabetes 2 3 Short Title: Muscle strength and cardiac autonomic neuropathy in T2DM 4 Chan-Hee Jung<sup>a</sup>, Yoon Young Cho<sup>a</sup>, Dug-Hyun Choi<sup>a</sup>, Bo-Yeon Kim<sup>a</sup>, Sang-Hee Jung<sup>b</sup>, Chul-Hee Kim<sup>a</sup>, Ji-Oh 5 Mok<sup>a</sup>\* 6 <sup>a</sup> Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University 7 College of Medicine, Bucheon, South Korea 8 <sup>b</sup> Department of Obstetrics and Gynecology, CHA Bundang Medical Center, CHA University, Seongnam, South 9 Korea 10 \* Corresponding author: 11 Ji-Oh Mok, 12 Division of Endocrinology and Metabolism, Department of Internal Medicine, 13 Soonchunhyang University College of Medicine, #170 Jomaru-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do, 420-767, South Korea 14 15 Tel: 82-32-621-5156 16 Fax: 82-32-621-5016 17 E-mail: hanna@schmc.ac.kr 18 ORCID: Ji-Oh Mok <a href="http://orcid.org/0000-0003-4882-1206">http://orcid.org/0000-0003-4882-1206</a> 19 Chan-Hee Jung http://orcid.org/0000-0001-8988-0187 20 Word count: 6591 21 Number of figures and tables: 1 figure, 3 tables 22 23 24 25 26 27 28 29 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 30

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Abstract Background: Several studies have investigated whether sarcopenia is associated with diabetic microvascular complications, but very few have examined associations between sarcopenia and cardiovascular autonomic neuropathy (CAN) in patients with type 2 diabetes mellitus (T2DM). Therefore, we investigated associations of muscle strength (handgrip strength [HGS]) and mass (appendicular skeletal muscle mass index [ASMI]) and CAN in patients with T2DM. Methods: We enrolled 342 T2DM patients (mean age 56.1±11.5 years; 58.2% male) in this retrospective, crosssectional study. Cardiovascular reflex tests were used to assess CAN according to Ewing's protocol. Relative HGS was determined after normalizing absolute HGS to body weight (HGS/body weight [kg]). We defined low HGS and low ASMI according to a consensus report of the Asian Group for Sarcopenia. Logistic regression analyses were carried out to assess the associations between relative HGS or ASMI quartiles and the presence of CAN in patients with T2DM. Results: The prevalence rates of CAN, low HGS, and low ASMI in the study subjects were 34.8%, 17.3%, and 18.7%, respectively. Low HGS was significantly more prevalent in patients with CAN than those without CAN (23.5% vs. 13.9%, p=0.025). The CAN scores were significantly and negatively correlated with relative HGS but not with ASMI. Relative HGS was negative correlated with age, glycated hemoglobin, fasting plasma glucose, hsCRP, body mass index, and HOMA-IR and positively correlated with ASMI. The prevalence of CAN gradually increased with decreasing quartile of relative HGS (28.4% in Q4, 31.8% in Q3, 34.2% in Q2, and 45.3% in Q1, p=0.02 for trend). Multivariable-adjusted prevalence ratios (PRs) for CAN, determined by comparing the first, second, and third quartiles with the fourth quartile of relative HGS, were 4.4 with a 95% confidence interval (95% CI) of [1.1 to 17.3]), 2.3 (95% CI [0.8 to 6.9]), and 1.2 (95% CI [0.4 to 3.7]), respectively. The prevalence of CAN and the PRs (95% [CI]) for CAN based on ASMI were not statistically significant. Conclusions: Our findings suggest that low muscle strength rather than low muscle mass was significantly associated with the presence of CAN. Therefore, HGS testing could help identify patients who would benefit from screening for earlier diagnosis of CAN. Keywords: appendicular skeletal muscle mass; cardiovascular autonomic neuropathy; handgrip strength; muscle

mass; muscle strength; type 2 diabetes

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

Introduction

Cardiovascular autonomic neuropathy (CAN) refers to impaired autonomic control of the heart and vessels and is a common microvascular complication of diabetes. 1,2 Numerous studies have reported that CAN is associated with life-threatening clinical entities, such as silent myocardial ischemia, coronary artery disease, peri-operative cardiovascular (CV) instability, and cardiac arrhythmia, resulting in increased cardiovascular and all-cause mortality.<sup>3-7</sup> Although there is definitive evidence of the prognostic relevance of CAN, it is underdiagnosed and one of the most overlooked complications of diabetes. 1,2 Timely diagnosis and efforts to overcome underdiagnosis of CAN are important to avoid serious events. One strategy to overcome under-diagnosis of CAN is to select candidates for active screening based on well known risk factors for the development and progression of CAN in patients with T2DM, such as hyperglycemia, hypertension (HTN), dyslipidemia, and obesity; additional risk factors need to be identified to effectively predict CAN. 8-12 Sarcopenia is defined as the loss of skeletal muscle mass and reduced muscle strength and/or physical performance.<sup>13</sup> In patients with T2DM, the presence of sarcopenia is receiving growing attention due to its increasing prevalence and the strong negative impact on prognosis.<sup>14</sup> Previous studies revealed a bidirectional relationship between sarcopenia and diabetic vascular complications. 14-16 Several studies have reported associations between sarcopenia and other diabetic microvascular complications <sup>17,18</sup> but, to our knowledge, there have been very few studies investigating the association between sarcopenia and CAN in T2DM. 19,20 Previous studies have reported subjects with sarcopenia had a greater impairment of cardiac autonomic function and heart rate variability (HRV) than those without sarcopenia. 21,22 However, most such studies were carried out in obese patients, operated patients, or elderly individuals without DM. 21,22 Because there have been very few studies evaluating the impact of sarcopenia on CAN in subjects with T2DM, our goal in this study was to investigate the relationships between CAN and two markers of sarcopenia (muscle strength and mass) in Korean patients with T2DM. Association between sarcopenia and CAN could help identify patients who would benefit from active screening for early diagnosis of CAN. Furthermore, interventions to modify sarcopenia may improve the prognosis of patients with CAN.

Methods

Study subjects

We conducted a retrospective, cross-sectional study of patients with T2DM who were treated at Soonchunhyang University Bucheon Hospital between April 2020 and July 2023. Among patients who were treated at the Endocrinology and Metabolism Clinic, 342 who underwent handgrip strength measurement and bioelectrical impedance analysis (BIA) and were assessed for CAN were enrolled in this study. The study protocol was approved by the Institutional Review Board (IRB) of Soonchunhyang University School of Medicine, Bucheon

approved by the histitutional Review Board (IRB) of Soonchumiyang University School of Medicine, Bucheon

Hospital (IRB number: 2024-04-001). The IRB waived the requirement for informed consent owing to the

retrospective design of this medical record review study.

# Assessment of muscle strength and muscle mass

Muscle strength was evaluated by HGS testing twice for each hand using a Smedley analog hand dynamometer (No. 04125; MIS, Tokyo, Japan) in a standing position, and the maximum value was used in the analyses. Relative HGS was calculated as absolute HGS (kg) divided by body weight to reduce the impact of body size.<sup>23</sup> We used bioimpedance analysis (BIA) to assess muscle mass. Appendicular skeletal muscle mass (ASM) was calculated by summing the lean mass in the arms and legs, which primarily represents skeletal muscle mass. The ASM index (ASMI) was calculated as ASM divided by height squared (ASM/Ht²; kg/m²). According to the consensus report of the Asian Working Group for Sarcopenia, we defined low muscle strength as HGS <26 kg for men and <18 kg for women and defined low muscle mass as ASMI <7 kg/m² in men and <5.7 kg/m² in women.<sup>13</sup> Subjects were divided into relative HGS quartiles or ASMI quartiles for statistical analysis.

#### Diagnosis of CAN

Autonomic function tests (AFT) were performed by a single operator in the morning in a quiet room, and the results were analyzed by one investigator. The subject was instructed to avoid consuming food, coffee, alcohol, and smoking for at least 2 h before the tests. The presence of CAN was assessed using the five standard non-invasive cardiovascular reflex tests (CVRTs) proposed by Ewing and Clarke more than 30 years ago [24] and that are now considered the cornerstone of diagnosis. The five CVRTs are the heart rate (HR) responses to (i) deep breathing (beat-to-beat variation), (ii) standing (30:15 ratio), and (iii) the Valsalva maneuver and the blood pressure (BP) response to (iv) standing and (v) a sustained handgrip. The CVRTs were assessed automatically from electrocardiography recordings using the DICAN evaluation system (Medicore Co., Ltd., Seoul, Korea).

Each CVRT was assigned a score of 0, 0.5, or 1 depending on whether the result was normal, borderline, or abnormal, respectively as previously described by Bellavere et al.<sup>25</sup> The presence of CAN was quantified by summing the scores of the five tests, and was defined as the presence of at least two abnormal tests or an autonomic neuropathy score  $\geq$ 2.

### Other covariates

Height and weight were measured to the nearest 0.1 cm and 0.1 kg, respectively. Body mass index (BMI) was calculated as body weight (kg) divided by height squared (meters). Blood samples were collected after overnight fasting. Glycated hemoglobin (HbA1c) was measured by ion-exchange high-performance liquid chromatography (Bio-Rad, Hercules, CA, USA) using a methodology aligned with the Diabetes Control and Complications Trial and National Glycohemoglobin Standardization Program standards. Estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease study equation, and the urine albumin-to-creatinine ratio (ACR) was assessed in spot urine specimens. Insulin resistance (IR) status was evaluated using the formula for the homeostasis model assessment–insulin resistance (HOMA-IR) index: (fasting insulin [μIU/mL] × fasting plasma glucose [mmol/L])/22.5.

### Statistical analysis

Data are reported as mean ± standard deviation (SD) or median (interquartile range) for continuous variables or as number of subjects (percentage) for categorical variables. The baseline characteristics of the study subjects according to the presence of CAN were compared using two-sample independent *t* tests for continuous variables and Chi-square tests for categorical variables as appropriate. To evaluate linear trends in the prevalence of CAN according to relative HGS and ASMI quartiles, *p* values were calculated using linear-by-linear association tests for categorical variables. Correlations between relative HGS, ASMI, and CAN score were assessed using the Spearman's rank correlation coefficient. Multivariate logistic regression analyses were performed to estimate the independent effects of relative HGS or ASMI quartile on the prevalence ratios (PRs) of CAN after adjustment for possible confounding factors (age, sex, BMI, current alcohol drinking, current smoking, duration of diabetes, HTN, HbA1c, triglyceride (TG), low density lipoprotein-cholesterol (LDL-C), eGFR, ACR, high-sensitivity c-reactive protein (hsCRP), HOMA-IR, beta-blockers, angiotensin-receptor blockers (ARBs), sodium-glucose cotransporter 2 inhibitors (SGLT2is), and insulin treatment). Skewed variables (hsCRP, TG, and ACR) were transformed logarithmically to improve normality before analyses. P values less than 0.05 were

234 **Results** 235 General characteristics of the subjects 236 The general characteristics of the study subjects are presented in Table 1. A total of 342 Korean T2DM patients 237 (199 male, 143 female, mean age 56.1±11.5 years) was enrolled in this retrospective, cross-sectional study. The 238 CAN prevalence was 34.8% (n=119), and the mean BMI and duration of DM were 25.7 kg/m<sup>2</sup> and 7.0 years, 239 respectively. The mean HbA1c of the study population was 8.5%, and the proportions of subjects treated with 240 oral hypoglycemic agents (OHA) or insulin were 65.2% and 15.8%, respectively. The mean HGS and ASMI were 29.7 kg and 7.3 kg/m<sup>2</sup>, respectively, and the proportion (number) of patients with low HGS and low ASMI 241 242 were 17.3% (n=59) and 18.7% (n=64). 243 244 Comparisons of clinical characteristics according to the presence or absence of CAN 245 The general characteristics of subjects according to the presence or absence of CAN are presented in Table 1. 246 The mean HGS and relative HGS were lower in subjects with CAN than in subjects without CAN (27.6 kg vs. 247 30.8 kg, p=0.004, 0.40 vs. 0.44, p=0.006, respectively). A greater proportion of subjects with CAN had low 248 HGS than those without CAN (23.5% vs. 13.9%, p=0.025). There were no significant differences in mean age, 249 duration of DM, BMI, HTN, glucose parameters, lipid profiles, eGFR, ACR, hsCRP, and HOMA-IR according 250 to the presence or absence of CAN. In addition, there were no significant differences in treatment modalities 251 such as insulin or OHA between subjects with CAN and those without CAN. The proportion of subjects using 252 SGLT2is or beta-blockers was significantly larger in subjects without CAN than those with CAN (17.5% vs. 253 7.6%, p=0.004, 6.3% vs. 1.7, p=0.011, respectively), and use of ARB was more prevalent in those with CAN 254 than those without CAN (30.3 % vs. 27.4%, p=0.042). 255 256 Prevalence of CAN according to relative HGS and ASMI quartiles 257 The prevalence of CAN according to relative HGS and ASMI quartiles is shown in Figure 1. The prevalence 258 declined significantly and progressively from the lowest to highest quartiles of relative HGS (45.3%, 34.2%, 259 31.8%, and 28.4%, respectively, p=0.02 for trend; Fig. 1[a]). On the other hand, the prevalence of CAN did not 260 differ from the lowest to highest quartiles of ASMI (36.8%, 35.2%, 34.5%, and 33%, respectively, p=0.197 for 261 trend; Fig. 1[b]). 262

Bivariate correlations of CAN score and relative HGS and ASMI with clinical variables

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281282

283

284

285

286

287

288

Correlations of CAN score, relative HGS, and ASMI with clinical variables are shown in Table 2. The CAN score showed a significant negative correlation with relative HGS (r=-0.137, p=0.012). However, there was no significant correlation between CAN score and ASMI. Relative HGS showed significant negative correlations with age, FBS, HbA1c, hsCRP, BMI, and HOMA-IR (r=-0.116, p=0.032; r=-0.132, p=0.015; r=-0.119, p=0.03; r=-0.201, p=0.003; r=-0.387, p<0.001; and r=-0.198, p=0.001, respectively) and a positive correlation with ASMI (r=0.334, p<0.001). The ASMI was negatively correlated with age and HDL-C (r=-0.403, p<0.001; r=-0.172, p=0.002, respectively) and positively correlated with TG, eGFR, BMI, and HOMA-IR (r=0.192, p<0.001; r=0.158, p=0.003; r=0.439, p<0.001; and r=0.12, p=0.049, respectively). Associations between CAN and relative HGS or ASMI quartile Multivariate logistic regression analysis adjusted for confounding variables was used to evaluate the associations between HGS, ASMI, and CAN (Table 3). When the highest relative HGS quartile group was used as a reference in the univariate model, patients in the lowest quartile (Q1) were 2.1-fold more likely to have CAN (OR 2.1; 95% CI [1.1 to 3.9]). This significant association for group O1 remained even after adjusting for age, duration of DM, HTN, smoking, alcohol, BMI, HbA1c, eGFR, ACR, TC, hsCRP, HOMA-IR, insulin treatment, SGLT2is, beta-blockers, and ARBs (OR 4.4, 95% CI [1.1 to 17.3]). However, there were no significant association between ASMI and CAN in either the unadjusted model or after multivariate adjustment.

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

**Discussion** We demonstrated that T2DM patients with low HGS are at a higher risk for the presence of CAN; however, low ASMI was not associated with the presence of CAN. These findings suggest that assessment of muscle strength using HGS could be invaluable in clinical practice to identify high-risk T2DM subjects who require earlier and active screening for CAN. There is considerable variation in the reported prevalence of CAN, depending upon the diagnostic criteria, test tool, interpretation of results, and study population.<sup>2</sup> The prevalence of clinical and subclinical CAN has been estimated to be 20–65% of diabetic patients, which is greater than the prevalence of other diabetic complications. <sup>2,26</sup> There is definitive evidence of the prognostic relevance of CAN for all-cause and CV mortality, and the risks are increased even at an asymptomatic stage.<sup>27</sup> Despite the importance of early detection of CAN, there are several possible barriers to testing: there is no harmonized definition of CAN, there is a wide variety of tools for assessing CAN, testing can be time-consuming and cumbersome, the results may be difficult to interpret, specific treatments for CAN are lacking, and testing may be considered unnecessary in asymptomatic cases.<sup>28</sup> Despite these barriers to testing, screening for CAN using Ewing's tests and HRV may allow diagnosis of at an earlier stage where risk factor modification is possible and reversibility is more likely. The established risk factors for development and progression of CAN are age, duration of diabetes, glycemic control, JTN, dyslipidemia, obesity, and smoking. 9,11,29 In addition, some studies have suggested glycemic variability, vitamin D, oxidative stress, and chronic inflammation as additional risk factors for CAN. 30-32 There are a few reports in the literature correlating sarcopenia with cardiac autonomic modulation. Early studies suggested that low muscle mass and muscle strength lead to reduced parasympathetic modulation and may be associated with abnormal autonomic modulation. A cross-sectional study of 76 elderly Brazilians showed that greater impairment of HRV was evident in subjects with sarcopenia than in those without sarcopenia.<sup>22</sup> In the study, muscular strength was assessed using HGS, muscle mass was assessed using the skeletal muscle index, and cardiac autonomic modulation was evaluated using a heart rate (HR) monitor to record five minutes of successive RR intervals. The analysis of the RR-interval variability was carried out in time and frequency domains. The non-sarcopenia group was that with adequate muscle strength and physical performance but

insufficient muscle mass or adequate muscle mass. Sarcopenia was defined as insufficient muscle mass plus

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

insufficient muscle strength and/or poor physical performance. The parameters of autonomic heart rate modulation differed significantly between elderly sarcopenic and non-sarcopenic participants. Elderly sarcopenic participants exhibited lower parasympathetic-associated modulation. Baek et al. investigated the relationship between overweight with low muscle mass and cardiac autonomic function as assessed by HRV in a five-min ECG recording in 1,150 healthy Korean workers.<sup>21</sup> The overweight group showed reduced parasympathetic modulation compared with the non-overweight group. In addition, the overweight-with-lowmuscle-mass group had a lower HRV than the overweight-with-high-muscle-mass group. Hyperinsulinemia and IR can induce the development of a sympathovagal imbalance with SNS predominance<sup>33</sup>; hyperinsulinemia-induced SNS activation may then result in further IR and hyperinsulinemia. Weight loss using lifestyle interventions and bariatric surgery may help improve cardiac autonomic function by reducing IR and hyperinsulinemia, leading to a reduction in SNS activation. Several studies have reported that weight reduction through bariatric surgery (BS) improves cardiac autonomic modulation.<sup>34,35</sup> Furthermore, the presence of low muscle mass and/or strength in the preoperative period has been shown to attenuate the improvement in cardiac autonomic function after BS compared with patients without sarcopenia.<sup>36</sup> A recent study by Carvalho et al. showed that women who underwent BS experienced less of an improvement of HRV during the follow-up period among women with low muscle mass and /or handgrip strength.<sup>36</sup> To the best of our knowledge, there have been few studies assessing associations of sarcopenia and CAN in T2DM, and the findings were not consistent with those of our study. 19,20 The primary aim of the study by Mikura et al. was to investigate the association between sarcopenia and severity of diabetic peripheral neuropathy (DPN) in 261 Japanese patients (median age; 67 years, median duration of DM; 10 years). 19 They also evaluated the association of autonomic neuropathy and sarcopenia. The coefficient of variation of the R-R interval was assessed using ECG as a marker of autonomic function, and autonomic neuropathy was noted if CV R-R was lower than the reference ranges. In addition, sarcopenia was identified based on the AWGS 2019 diagnostic criteria, consistent with our current study. The Mikura et al. study showed that neither autonomic neuropathy nor DPN was significantly correlated with sarcopenia. Another study by Ozgur Y et al. examined the relationships between several diabetic neuropathy subtypes and low muscle mass/low muscle strength in a cross-sectional study of 602 diabetic patients (mean age; 60.2 years).<sup>20</sup> In the study, diabetic neuropathy was classified into subtypes of diabetic sensorimotor polyneuropathy or diabetic autonomic neuropathies (DAN), and DAN was further subclassified into four subgroups of gastrointestinal autonomic neuropathy, genitourinary autonomic

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

neuropathy, sudomotor autonomic neuropathy, and CAN. The Ozgur study used HR while sitting, HR response to standing, and BP response to standing to diagnose CAN in the presence of abnormality in two of three tests. When the DAN sub-groups were considered, the prevalence of CAN did not differ significantly between the sarcopenic and non-sarcopenic groups. In addition, there was no significant association between CAN and low muscle mass or low muscle strength in logistic regression analyses. Specifically, the prevalence of diabetic neuropathy in the low muscle strength group was greater than in the low muscle mass group. They found that although the skeletal muscle mass index was higher in low muscle strength when compared to low muscle mass group, their muscle qualities were much lower in low muscle strength. The latter finding suggests that loss of muscle strength is more important than loss of muscle mass in terms of the prognosis of diabetic neuropathy. In our study, subjects with low HGS had a greater CAN prevalence than subjects with low ASMI (47.5% vs. 31.2%, data not shown). The prevalence of CAN increased progressively with decreasing quartile of relative HGS, and the lowest quartile of relative HGS was significantly associated with the PR of CAN. However, the prevalence of CAN and PRs for CAN based on ASMI were not significant. Our findings study also suggest that muscle strength may be a more useful diagnostic marker of the presence of CAN than muscle mass. Most previous studies used HRV derived from ECG recordings as a diagnostic tool for assessment of CAN, whereas there have been no studies investigating the correlation of CAN score based on CVRTs as assessed by Ewing's test and sarcopenia parameters. Although agreement between indices of HRV derived from ECGs and CVRTs has been reported, CVRTs are the gold standard for the diagnosis of CAN.<sup>37</sup> We analyzed the correlations of relative HGS, ASMI, and CAN score with clinical parameters and found that relative HGS was significantly and negatively correlated with hsCRP, BMI, HOMA-IR, and glucose parameters. The significant correlations of relative HGS with inflammatory markers, obesity, IR index, and glycemia, all of which are risk factors of CAN, indicate that they contribute to the association between muscle strength and presence of CAN. On the other hand, ASMI was marginally and positively correlated with HOMA-IR, but there was no correlation with hsCRP and glucose parameters. Overall, the CAN score was significantly correlated only with relative HGS not with ASMI. In a Danish multicenter cross-sectional study of T2DM patients, CAN was independently associated with high BP, BMI, and smoking. 26 However, in our study, the CAN score was not significantly correlated with duration of diabetes, HbA1c, lipid profile, hsCRP, eGFR, ACR, BMI, or HOMA-IR. Previous studies also reported that age, duration of diabetes, eGFR, BP, lipid profile, and HbA1c did not differ between subjects with and without CAN.<sup>30</sup>

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

Among sarcopenia parameters, muscle strength may represent muscle quality or function. Several studies have reported that low muscle strength, but not muscle mass, is associated with poor physical function and higher mortality.<sup>23,38</sup>, and that muscle strength more strongly influences various diabetic complications than does muscle mass in patients with T2DM.<sup>17</sup> These findings suggest that measuring muscle mass alone may not be sufficient to predict and protect against DM complications, and preservation of muscle strength may be more important. A previous joint international longitudinal study suggested that HGS is a useful predictor of the risk of CVD and mortality.<sup>23</sup> In addition, a subanalysis of the ORIGIN trial showed HGS to be associated with CVD mortality in patients with T2DM.<sup>38</sup> The mechanisms underlying the association between sarcopenia and cardiac autonomic dysfunction are unclear, but some explanations can be suggested. First, CAN and sarcopenia have multifactorial etiologies and common risk factors. Hyperinsulinemia or IR results in early CAN through the development of a sympathovagal imbalance with SNS activation. 33,39, while IR has also been suggested as a main underlying mechanism of sarcopenia. In addition, increased low-grade chronic inflammation is a common feature in patients with sarcopenia and has been associated with decline in muscle mass and strength and reduced HRV. 40 Second, increased reactive oxygen species and mitochondrial dysfunction can lead to muscle wasting and autonomic dysfunction. 41,42 Third, the myokine irisin produced by skeletal muscle may serve as an important cross-organ messenger linking skeletal muscle with the brain, adipose tissue, and CV system to integrate energy expenditure with CV activity. 43 Irisin controls HR, modulates vagal tone, and promotes CV protection. 44 Previous studies showed a positive correlation between irisin and HGS in a multivariate analysis. 45,46 Irisin has been reported to be strongly associated with muscle strength and was recently suggested to be a candidate factor to explain the relationship between muscle strength and parasympathetic tone to the heart, promoting a cardioprotective role. 43,44 However, since serum irisin was not measured in our study, a direct causal relationship among irisin, muscle strength, and autonomic modulation in patients with T2DM needs to be further examined. While there is no conclusive evidence of a successful disease-modifying therapy, multifactorial interventions including glycemic control and weight loss might be effective. In addition, beta blockers and renin-angiotensinaldosterone system inhibitors are known to have a positive effect on autonomic dysfunction, and emerging data on SGLT2i suggest a modulatory effect on cardiovascular autonomic function. 47,48 In our current study,

adjustment of the models for these medications did not substantially change the results. One strength of the present study is that, to the best of our knowledge, it is the first to investigate directly the relationship between HGS and CAN using CVRTs in patients with T2DM. This study also has some limitations. First, we excluded patients with no CVRT, BIA, or HGS results, which led to a small sample size and a potential for selection bias. Second, because of the retrospective, cross-sectional nature of this study, we could not determine causality of the relationship between CAN and sarcopenia. Future prospective or interventional studies are needed to investigate the longitudinal associations among HGS, ASMI, and CAN in a large sample size. In conclusion, we demonstrated that HGS was associated with the presence of CAN in Korean patients with T2DM. We also found that ASMI was not associated with the presence of CAN. Low muscle strength is an important cause of morbidity in T2DM and CAN is also a serious complication. In patients with both low muscle strength and CAN, poor quality of life may be expected. Therefore, low muscle strength may be recognized with a simple HGS test performed in clinical practice, allowing early diagnosis of CAN.

**Author contributions** CHJ and JOM contributed to the conception and design of the study; CHJ, YYC, DHC, BYK, and CHK contributed to data collection and management; CHJ, YYC, DHC, BYK, SHJ, CHK, and JOM contributed to acquisition, analysis, or interpretation of the data; CHJ and SHJ contributed to writing the manuscript; JOM contributed to manuscript revision. All authors read and approved the final manuscript. Acknowledgements This study was supported by a grant from Soonchunhyang University. **ORCID** Chan-Hee Jung <a href="https://orcid.org/0000-0001-8988-0187">https://orcid.org/0000-0001-8988-0187</a> Ji-Oh Mok https://orcid.org/0000-0003-4882-1206 **Disclosures** None. **Conflicts of interest** The authors have no conflicts of interest to declare. **Ethical statement** The study was approved by the Institutional Review Board of Soonchunhyang University Bucheon Hospital. **Informed consent** Not applicable

## References

466

- 468 1. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation. 2007;115:387-397
- 469 2. Spallone V, Ziegler D, Freeman R, Bernardi L, Frontoni S, Pop-Busui R, Stevens M, Kempler P, Hilsted J,
- 470 Tesfaye S, Low P, Valensi P; Toronto Consensus Panel on Diabetic Neuropathy. Cardiovascular autonomic
- 471 neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes *Metab Res Rev*.
- 472 2011;27:639-653
- 473 3. Ewing DJ, Boland O, Neilson JM, Cho CG, Clarke BF. Autonomic neuropathy, QT interval lengthening, and
- unexpected deaths in male diabetic patients. *Diabetologia*. 1991;34:182-185
- 4. Gerritsen J, Dekker JM, TenVoorde BJ, Kostense PJ, Heine RJ, Bouter LM, Heethaar RM, Stehouwer CD.
- 476 Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes,
- 477 hypertension, or a history of cardiovascular disease: the Hoorn Study. *Diabetes Care*. 2001;24:1793-1798
- 5. Meyer C, Milat F, McGrath BP, Cameron J, Kotsopoulos D, Teede HJ. Vascular dysfunction and autonomic
- neuropathy in Type 2 diabetes. Diabet Med. 2004;21:746-751
- 480 6. Maser RE, Lenhard MJ. Cardiovascular autonomic neuropathy due to diabetes mellitus: clinical
- 481 manifestations, consequences, and treatment. J Clin Endocrinol Metab. 2005;90:5896-5903
- 482 7. Pop-Busui R, Evans GW, Gerstein HC, Fonseca V, Fleg JL, Hoogwerf BJ, Genuth S, Grimm RH, Corson MA,
- 483 Prineas R; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of cardiac autonomic
- 484 dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
- 485 Diabetes Care. 2010;33:1578-1584
- 486 8. Valensi P, Paries J, Attali JR. Cardiac autonomic neuropathy in diabetic patients: influence of diabetes
- 487 duration, obesity, and microangiopathic complications—the French multicenter study. Metabolism.
- 488 2003;52:815-820
- 489 9. Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent
- 490 large clinical trials. Curr Diab Rep. 2014;14:528
- 491 10. Guarino D, Nannipieri M, Iervasi G, Taddei S, Bruno RM. The role of the autonomic nervous system in the
- 492 pathophysiology of obesity. Front Physiol. 2017;8:665
- 493 11. Andersen ST, Witte DR, Fleischer J, Andersen H, Lauritzen T, Jorgensen ME, Jensen TS, Pop-Busui R,
- 494 Charles M. Risk factors for the presence and progression of cardiovascular autonomic neuropathy in type 2
- diabetes: ADDITION-Denmark. Diabetes Care. 2018;41:2586-2594

- 496 12. Williams SM, Eleftheriadou A, Alam U, Cuthbertson DJ, Wilding JPH. Cardiac Autonomic Neuropathy in
- 497 Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review. *Diabetes Ther*. 2019;10:1995-2021
- 498 13. Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, Jang HC, Kang L, Kim M, Kim S, et al.
- 499 Asian working group for sarcopenia 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med
- 500 Dir Assoc. 2020;21:300-307
- 501 14. Morley JE, Malmstrom TK, Rodriguez-Manas L, Sinclair AJ. Frailty, sarcopenia and diabetes. J Am Med
- 502 *Dir Assoc*. 2014;15:853-859
- 503 15. Boonpor J, Pell JP, Ho FK, Celis -Morales C, Gray SR. In people with type 2 diabetes, sarcopenia is
- associated with the incidence of cardiovascular disease: a prospective cohort study from the UK biobank.
- 505 *Diabetes Obes Metab.* 2024;26:524-531
- 16. Xia LF, Li JB, Tian GS, Jiang WR, Li YS, Lin CY, Qiu HN, Wu F, Wang JJ, Li CJ, et al. Effect of sarcopenia
- 507 on 10-year risk of atherosclerotic cardiovascular disease in patients with type 2 diabetes mellitus. Diabetes
- 508 Metab Syndr Obes. 2024;17:1621-1634
- 509 17. Fukuda T, Bouchi R, Takeuchi T, Nakano Y, Murakami M, Minami I, Izumiyama H, Hashimoto K,
- 510 Yoshimoto T, Ogawa Y. Association of diabetic retinopathy with both sarcopenia and muscle quality in patients
- with type 2 diabetes: a cross-sectional study. BMJ Open Diabetes Res Care. 2017;27:e000404
- 512 18. Wannarong T, Sukpornchairak P, Naweera W, Geiger CD, Ungprasert P. Association between diabetic
- 513 peripheral neuropathy and sarcopenia: A systematic review and meta-analysis. Geriatr Gerontol Int.
- 514 2022;22:785-789
- 515 19. Mikura K, Kodama E, Lida T, Imai H, Hashizume M, Kigawa Y, Tadokoro R, Sugisawa C, Endo K, Lizaka
- 516 T, et al. Association between sarcopenia and the severity of diabetic polyneuropathy assessed by nerve
- 517 conduction studies in Japanese patients with type 2 diabetes mellitus. *J Diabetes Invest.* 2022;13:1357-1365
- 518 20. Ozgur Y, Akin S, Keskin O. Relationship between diabetic neuropathy and sarcopenia. *Prim Care Diabetes*.
- 519 2019;13:521-528
- 520 21. Baek J, Park D, Kim I, Won JU, Hwang J, Roh J. Autonomic dysfunction of overweight combined with low
- 521 muscle mass. Clin Auton Res. 2013;23:325-331
- 522 22. Freitas VP, Passos RDS, Oliveira AA, Ribeiro IJS, Freire IV, Schettino L, Teles MF, Casotti CA, Pereira R.
- Sarcopenia is associated to an impaired autonomic heart rate modulation in community-dwelling old adults.
- 524 Arch Gerontol Geriatr. 2018;76:120-124
- 525 23. Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, Sayer AA. A review of the

- 526 measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age
- 527 Ageing. 2011;40:423-429
- 528 24. Ewing DJ, Martyn CN, Young RJ, Clarke BF. The value of cardiovascular autonomic function tests: 10 years
- 529 experience in diabetes. *Diabetes Care*. 1985;8:491-498
- 530 25. Bellavere F, Bosello G, Fedele D, Cardone C, Ferri M. Diagnosis and management of diabetic autonomic
- 531 neuropathy. *Br Med J (Clin Res Ed)*. 1983;287:61
- 532 26. Fleischer J, Yderstraede K, Gulichsen E, Jakobsen PE, LervangHH, Eldrup E, Nygaard H, Tarnow L,
- 533 Ejskjaer N. Cardiovascular autonomic neuropathy is associated with macrovascular risk factors in type 2
- 534 diabetes: new technology used for routine large-scale screening adds new insight. J Diabetes Sci Technol.
- 535 2014;8:874-880
- 536 27. Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: a position statement by the American
- 537 Diabetes Association. Diabetes Care. 2017;40:136-154
- 538 28. Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V,
- Vinik A, et al. Diabetic neuropathies: Update on definitions, diagnostic criteria, estimation of severity, and
- 540 treatments. *Diabetes Care*. 2010;33:2285-2293
- 541 29. Voulgari C, Psallas M, Kokkinos A, Argiana V, Katsilambros N, Tentolouris N. The association between
- cardiac autonomic neuropathy with metabolic and other factors in subjects with type 1 and type 2 diabetes. J
- 543 *Diabetes Complications*. 2011;25:159-167
- 544 30. Gad H, Elgassim E, Mohammed I, Alhaddad AY, Aly HAHZ, Cabibihan J, Al-Ali A, Sadasivuni KK,
- Petropoulos I, Ponirakis G, et al. Cardiovascular autonomic neuropathy is associated with increased glycemic
- variability driven by hyperglycemia rather than hypoglycemia in patients with diabetes. *Diabetes Res Clin Pract.*
- 547 2023;200:110670
- 548 31. Jung CH, Jung SH, Kim KJ, Kim BY, Kim CH, Kang SK, Mok JO. The relationship between vitamin D
- status and cardiac au-tonomic neuropathy in patients with type 2 diabetes mellitus. Diab Vasc Dis Res.
- 550 2015;12:342-51
- 32. Herder C, Schamarek I, Nowotny B, Carstensen-Kirberg M, Straßburger K, Nowotny P, Kannenberg JM,
- 552 Strom A, Puttgen S, Mussig K, et al; German Diabetes Study Group. Inflammatory markers are associated with
- 553 cardiac autonomic dysfunction in recent-onset type 2 diabetes. *Heart*. 2017;103:63-70
- 33. Saito I, Maruyama K, Eguchi E, Kato T, Kawamura R, Takata Y, Onuma H, Osawa H, Tanigawa T. Low
- heart rate variability and sympathetic dominance modifies the association between insulin resistance and

- metabolic syndrome—the Toon Health Study. *Circ J.* 2017;81:1447-1453
- 557 34. Kokkinos A, Alexiadou K, Liaskos C, Argyrakopoulou G, Balla I, Tentolouris N, Moyssakis I,
- KatsilambrosN, Vafiadis I, Alexandrou A, et al. Improvement in cardiovascular indices after Roux-en-Y gastric
- bypass or sleeve gastrectomy for morbid obesity. *Obes Surg.* 2013;23:31-38
- 35. Benjamim CJR, Pontes YMM, de Sousa Junior FW, Porto AA, Bueno Junior CR, Marcelino da Silva AA,
- Ferro Cavalcante TC, Garner DM, Valenti VE. Does bariatric surgery improve cardiac autonomic modulation
- assessed by heart rate variability? A systematic review. Surg Obes Relat Dis. 2021;17:1497-1509
- 36. Crispim Carvalho NN, Baccin Martins VJ, da Nóbrega VA, de Arruda Neta ADCP, Cavalcante da Fonseca
- 564 LA, Bandeira F, de Brito Alves JL. Effects of Preoperative Sarcopenia-Related Parameters on Cardiac
- Autonomic Function in Women with Obesity Following Bariatric Surgery: A One-Year Prospective Study.
- 566 Nutrients. 2023;15:2656
- 567 37. Pop-Busui R, Backlund JC, Bebu I, Braffett BH, Lorenzi G, White NH, Lachin JM, Soliman EZ and
- 568 DCCT/EDIC Research Group. Utility of using electrocardiogram measures of heart rate variability as a measure
- of cardiovascular autonomic neuropathy in type 1 diabetes patients. J Diabetes Investig. 2022;13:125-133
- 570 38. Lopez-Jaramillo P, Cohen DD, Gomez-Arbelaez D, Bosch J, Dyal L, Yusuf S, Gerstein HC; ORIGIN trial
- 571 investigators. Association of handgrip strength to cardiovascular mortality in pre-diabetic and diabetic patients:
- a subanalysis of the ORIGIN trial. *Int J Cardiol*. 2014;174:458-461.
- 573 39. Williams S, Eleftheriadou A, Alam U, Cuthbertson DJ, Wilding JPH. Cardiac autonomic neuropathy in
- 574 obesity, the metabolic syndrome and prediabetes: A narrative review. *Diabetes Ther.* 2019;10:1995-2021
- 575 40. da Fonseca GWP, von Haehling S. Sarcopaenia complicating heart failure. Eur Heart J Suppl. 2019;21:L20–
- 576 L23
- 577 41. Tse G, Yan BP, Chan YW, Tian XY, Huang Y. Reactive oxygen species, endoplasmic reticulum stress and
- 578 mitochondrial dysfunction: The link with cardiac arrhythmogenesis. Front Physiol. 2016;7:313
- 579 42. Abrigo J, Elorza A, Riedel CA, Vilos C, Simon F, Cabrera D, Estrada L, Cabello-Verrugio C. Role of
- 580 oxidative stress as key regulator of muscle wasting during cachexia. Oxid Med Cell Longev. 2018;2018:2063179
- 581 43. Zhang W, Chang L, Zhang C, Zhang R, Li Z, Chai B, Li J, Chen E, Mulholland M. Central and peripheral
- 582 irisin differentially regulate blood pressure. Cardiovasc Drugs Ther. 2015;29:121-127
- 583 44. Brailoiu E, Deliu E, Sporici RA, Brailoiu GC. Irisin evokes bradycardia by activating cardiac-projecting
- neurons of nucleus ambiguous. *Physiol Rep.* 2015;3:e12419
- 45. Munoz IYM, Romero ESC, Padilla TC, Benitez JGS, Romero MSC, Morales LPM, Bravo GGH, Garcia JJG.

Association of irisin serum concentration and muscle strength in normal-weight and overweight young women. Front Endocrinol. 2019;10:621 46. Planella-Farrugia C, Comas F, Sabater-Masdeu M, Moreno M, Moreno-Navarrete JM, Rovira O, Ricart W, Fernandez-Real JM. Circulating irisin and myostatin as markers of muscle strength and physical condition in elderly subjects. Front Physiol. 2019;10:871 47. Colle SD, Morello F, Rabbia F, Milan A, Naso D, Puglisi E, Mulatero P, Veglio F. Antihypertensive drugs and the sympathetic nervous sysem. J Cardiovasc Pharmacol. 2007;50:487-496 48. Sano M. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. *J Cardiol*. 2018;71:471-6 

Table 1. General characteristics of study patients according to the presence of CAN

	Total	CAN (-)	CAN (+)	P-value
Frequency, n (%)	342	223 (65.2%)	119 (34.8%)	
Age (years)	56.1±11.5	55.4±11.6	57.4±11.3	0.123
Duration of diabetes	7.0±7.5	6.6±7.5	7.9±7.5	0.149
Sex (men), n (%)	199 (58.2%)	137 (61.4%)	62 (52.1%)	0.096
HbA1C (mmol/mol)	69.4±2.0	67.2±1.0	72.7±3.0	0.070
FPG (mmol/L)	8.42±2.89	8.26±2.73	8.72±3.15	0.185
Total cholesterol (mg/dL)	159±47	156±45	164±51	0.140
TG (mg/dL)	125 (90–178)	122 (90-173)	127 (91-195)	0.191
HDL-C (mg/dL)	47±11	47±11	47±11	0.778
LDL-C (mg/dL)	87±35	85±34	90±37	0.191
HTN, n (%)	119 (34.8%)	74 (33.6%)	45 (40.2%)	0.240
hsCRP (mg/L)	0.08 (0.04-0.22)	0.08 (0.04-0.23)	0.08 (0.04-0.21)	0.593
ACR	1.2 (0.6-3.7)	1.1 (0.6-3.2)	1.4 (0.6-6.2)	0.905
eGFR	90.1±17.0	90.6±17.4	87.2±20	0.096
HOMA-IR	2.9 (1.7-4.8)	2.8 (1.6-4.4)	3.2 (1.8-5.1)	0.095
BMI	25.7±4.0	25.7±3.9	25.8±4.1	0.703
HGS (kg)	29.7±9.6	30.8±9.4	27.6±9.6	0.004
Relative HGS	0.43±0.12	0.44±0.11	0.40±0.12	0.006
ASMI (kg/m²)	7.3±1.0	7.4±1.1	7.2±1.0	0.164
Low HGS, n (%)	59 (17.3%)	31 (13.9%)	28 (23.5%)	0.025
Low ASMI, n (%)	64 (18.7%)	44 (19.7%)	20 (16.8%)	0.509
Smoking, n (%)	89 (26%)	63 (28.3%)	26 (21.8%)	0.328
Alcohol, n (%)	110 (32.2%)	69 (30.9%)	41 (34.5%)	0.455
Diabetic retinopathy, n (%)	64 (25.4%)	37 (22.8%)	27 (30%)	0.211
DPN, n (%)	112 (41.8%)	66 (37.9%)	46 (48.9%)	0.081
OHA, n (%)	223 (65.2%)	149 (68%)	74 (66.1%)	0.718
Metformin, n (%)	213 (62.3%)	145 (65%)	68 (57.1%)	0.077
DPP4I, n (%)	132 (38.6%)	82 (36.8%)	50 (42%)	0.026
SGLT2I n, (%)	48 (14%)	39 (17.5%)	9 (7.6%)	0.004
GLP1RA n, (%)	17 (5%)	12 (5.4%)	5 (4.2%)	0.056
Insulin, n (%)	54 (15.8%)	34 (15.2%)	20 (16.8%)	0.051
ARB	97 (28.4%)	61 (27.4%)	36 (30.3%)	0.042
Beta blockers	16 (4.7%)	14 (6.3%)	2 (1.7%)	0.011

Data are reported as mean  $\pm$  standard deviation (SD) or median (interquartile range) or as number of subjects (percentage).

ACR, Albumin/creatinine ratio; ARB, angiotensin receptor blocker; ASMI, appendicular skeletal muscle index; BMI, body mass index; CAN, cardiovascular autonomic neuropathy; DPN, diabetic peripheral neuropathy; DPP4I, dipeptidyl peptidase-4 inhibitor; FPG, fasting plasma glucose; GLP1RA, glucagon like peptide-1 receptor agonist; HbA1C, glycated hemoglobin; HDL-C, high density lipoprotein-cholesterol; HGS, handgrip strength; HOMA-IR, homeostasis model assessment—insulin resistance; hsCRP, high-sensitivity c-reactive protein; LDL-C, low density lipoprotein-cholesterol; OHA, oral hypoglycemic agent; SGLT2I, sodium-glucose cotransporter 2 inhibitor; TG, triglyceride


Table 2. Correlation analyses for relative HGS, ASMI, and CAN score with clinical variables in total subjects

	Relative HGS	ASMI	CAN Score
	r (p-value)	R (p-value)	R (p-value)
Relative HGS	- "	0.334 (<0.001)	-0.137 (0.012)
ASMI	0.334 (<0.001)	-	-0.051 (0.350)
CAN score	-0.137 (0.012)	-0.051 (0.350)	-
Age (years)	-0.116 (0.032)	-0.403 (<0.001)	0.09 (0.097)
Duration of diabetes (years)	-0.01 (0.861)	-0.042 (0.445)	0.061 (0.263)
FPG (mg/dL)	-0.132 (0.015)	-0.021 (0.705)	0.023 (0.668)
HbA1c (%)	-0.119 (0.03)	-0.023 (0.675)	0.102 (0.064)
TC (mg/dL)	-0.06 (0.272)	-0.014 (0.790)	0.006 (0.910)
TG (mg/dL)	-0.103 (0.057)	0.192 (<0.001)	-0.033 (0.542)
HDL-C (mg/dL)	-0.026 (0.640)	-0.172 (0.002)	0.07 (0.215)
LDL-C (mg/dL)	-0.041 (0.461)	0.021 (0.707)	0.008 (0.881)
hsCRP (mg/L)	-0.201 (0.003)	0.047 (0.486)	-0.02 (0.770)
ACR	-0.108 (0.071)	0.017 (0.780)	0.03 (0.620)
eGFR	0.036 (0.513)	0.158 (0.003)	-0.089 (0.101)
BMI	-0.387 (<0.001)	0.439 (<0.001)	-0.003 (0.959)
HOMA-IR	-0.198 (0.001)	0.12 (0.049)	0.027 (0.659)

ACR, Albumin/creatinine ratio; ASMI, appendicular skeletal muscle index; BMI, body mass index; CAN, cardiovascular autonomic neuropathy; FPG, fasting plasma glucose; HbA1C, glycated hemoglobin; HDL-C, high density lipoprotein-cholesterol; HGS, handgrip strength; HOMA-IR, homeostasis model assessment—insulin resistance; hsCRP, high-sensitivity c-reactive protein; LDL-C, low density lipoprotein-cholesterol; TG, triglyceride

Fig. 1. The prevalence of CAN in study patients according to quartile of relative HGS or ASMI [a]

#### P=0.197 for trend



697 [b] 

P=0.02 for trend




Table 3. Multiple logistic regression analysis of the association of sarcopenia with presence of CAN

	Model 1		Model 2	
	PRs (95% CI)	P-value	PRs (95% CI)	P-value
Relative HGS				
Quartile 1	2.1 [1.1, 3.9]	0.021	4.4 [1.1, 17.3]	0.033
Quartile 2	1.3 [0.7, 2.5]	0.422	2.3 [0.8, 6.9]	0.126
Quartile 3	1.2 [0.6, 2.2]	0.622	1.2 [0.4, 3.7]	0.731
Quartile 4	1 [Reference]		1 [Reference]	
ASMI				
Quartile 1	1.2 [0.6, 2.2]	0.601	1.4 [0.3, 6.7]	0.648
Quartile 2	1.1 [0.6, 2.1]	0.75	1.2 [0.3, 5.3]	0.775
Quartile 3	1.1 [0.6, 2.0]	0.831	1.1 [0.3, 4.0]	0.835
Quartile 4	1 [Reference]		1 [Reference]	